Literature DB >> 25510390

Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations.

.   

Abstract

This article presents the World Health Organization's (WHO) recommendations for the use of vaccines against diseases caused by human papillomaviruses (HPV) from the WHO position paper on Human papillomavirus vaccines: WHO position paper - October 2014, recently published in the Weekly Epidemiological Record [1]. This position paper summarizes the most recent developments in the field of HPV vaccines and the WHO position on HPV vaccine schedules in females. This document replaces the first WHO position paper on vaccines against diseases caused by HPV published in 2009 [2]. Footnotes to this paper provide a number of core references. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. This paper reflects the recommendations of WHO's Strategic Advisory Group of Experts (SAGE) on immunization. These recommendations were discussed by SAGE at its April 2014 meeting. Evidence presented at the meeting can be accessed at http://www.who.int/immunization/sage/previous/en/index.html.
Copyright © 2015 The Author. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  HPV; Human papillomavirus vaccine; WHO position paper; WHO recommendations

Mesh:

Substances:

Year:  2014        PMID: 25510390     DOI: 10.1016/j.vaccine.2014.12.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women.

Authors:  Nicolas F Schlecht; Angela Diaz; Viswanathan Shankar; Arnold H Szporn; Maoxin Wu; Anne Nucci-Sack; Ken Peake; Howard D Strickler; Robert D Burk
Journal:  J Infect Dis       Date:  2016-10-12       Impact factor: 5.226

2.  Including males in Canadian human papillomavirus vaccination programs: a policy analysis.

Authors:  Gilla K Shapiro; Samara Perez; Zeev Rosberger
Journal:  CMAJ       Date:  2016-04-25       Impact factor: 8.262

3.  Chinese mothers' intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province.

Authors:  Yulan Lin; Zhitai Su; Fulian Chen; Qinjian Zhao; Gregory D Zimet; Haridah Alias; Shuqiong He; Zhijian Hu; Li Ping Wong
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

Review 4.  Malignancies in women with HIV infection.

Authors:  Nora T Oliver; Elizabeth Y Chiao
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

5.  Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion.

Authors:  Jennifer L St Sauver; Lila J Finney Rutten; Jon O Ebbert; Debra J Jacobson; Michaela E McGree; Robert M Jacobson
Journal:  Prev Med       Date:  2016-02-28       Impact factor: 4.018

6.  Annual prevalence and economic burden of genital warts in Korea: Health Insurance Review and Assessment (HIRA) service data from 2007 to 2015.

Authors:  Y J Park; J M Kim; B R Lee; T H Kim; E G Lee
Journal:  Epidemiol Infect       Date:  2017-12-13       Impact factor: 4.434

7.  The Subcellular Localisation of the Human Papillomavirus (HPV) 16 E7 Protein in Cervical Cancer Cells and Its Perturbation by RNA Aptamers.

Authors:  Özlem Cesur; Clare Nicol; Helen Groves; Jamel Mankouri; George Eric Blair; Nicola J Stonehouse
Journal:  Viruses       Date:  2015-06-26       Impact factor: 5.048

Review 8.  A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.

Authors:  Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas
Journal:  Front Public Health       Date:  2021-07-01

9.  Non-inferior antibody levels for HPV16/18 after extended two-dose schedules compared with a six-month interval: findings of a systematic review and meta-analysis.

Authors:  Aneisha Collins-Fairclough; Robine Donken; Bohdan Nosyk; Simon Dobson; Gina Ogilivie; Manish Sadarangani
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 4.526

Review 10.  HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know.

Authors:  Ingrid Herta Rotstein Grein; Noortje Groot; Marcela Ignacchiti Lacerda; Nico Wulffraat; Gecilmara Pileggi
Journal:  Pediatr Rheumatol Online J       Date:  2016-03-08       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.